171-LB: A Pilot Study to Evaluate the Utility of an Interconnected Diabetes Management Solution in People with T2D

Abstract

Use of remote monitoring/smartphones can lower HbA1c in T2D. This 12-week (W) single-arm pilot evaluated the utility of an investigational Interconnected Diabetes Management Solution (IDMS) using remote behavioral coaching from a certified diabetes educator (guide) and a mobile application (app). The app and call(s) allowed user (service member)-guide communication and monitoring of guide-directed tasks (short, time-limited behavioral interventions to improve testing, food choice, activity, stress and sleep). Members (adults: confirmed T2D; HbA1c 7-11%) provided quantitative and qualitative data. Members used a wireless enabled Contour® Next ONE blood glucose smart meter linked to the app on their mobile device. ∆HbA1c (0-12W) was evaluated. Baseline characteristics, n=58 (% or mean): male, 62%; age, 62 years; Caucasian, 88%; hypertension, 50%; BMI ≥30 kg/m2, 60%; hyperlipidemia, 48%; neuropathy, 28%; retinopathy, 12%; CVD, 10%; T2D for >10 years, 71%. Mean %-HbA1c (±SEM) significantly decreased from 8.44 (0.08) to 8.01 (0.08) at W12: -0.43%, p<0.0007 (Figure). A significant decrease in HbA1c was present in individuals with no change to diabetes medication(s). The investigator deemed all adverse events (n=59) unrelated to the IDMS. Conclusion: mean HbA1c significantly decreased independent of changes to medication(s), suggesting improved self-care and glycemic control. Figure. Disclosure L.J. Klaff: Research Support; Self; Abbott, Ascensia Diabetes Care, Cnoga Medical, Gan & Lee Pharmaceuticals, Lilly Diabetes, Medtronic MiniMed, Inc., Novo Nordisk Inc., REMD Biotherapeutics, Sanofi, Senseonics, Xeris Pharmaceuticals, Inc., Zealand Pharma A/S. T. Maier: Employee; Self; Ascensia Diabetes Care. J.M. Richardson: Employee; Self; Ascensia Diabetes Care. Employee; Spouse/Partner; Ascensia Diabetes Care. S. Pardo: Employee; Self; Ascensia Diabetes Care.